![](https://newswiredesk.com/wp-content/uploads/2023/09/6d43a1b15a5495d22497d3aa7a06feb7.png)
DelveInsight’s “Obesity- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the obesity, historical and forecasted epidemiology as well as the obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Obesity Overview
Obesity is recognized as a chronic or noncommunicable disease, which is a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity, or body fatness which can manifest metabolically and not just with respect to the size of the body. Obesity proceeds from an energy imbalance between calories consumed and the calories expended, creating an energy surplus and a state of positive energy balance resulting in excess body weight. Hereditary factors – genetics, family history, racial/ethnic differences – and particular socioeconomic and sociocultural milieus have been shown to affect the risk of obesity. As per the World Health Organization (WHO), obesity is classified on the basis of body mass index (BMI). BMI is further evaluated in terms of fat distribution via the waist–hip ratio and total cardiovascular risk factors. In children, a healthy weight varies according to age and gender. Obesity results from an interaction between an individual’s genetic predisposition to weight gain and environmental influences. The severe forms and majority of the early-onset monogenic forms of obesity have aroused from gene mutations in the leptin-melanocortin axis, particularly LEPR encoding for the leptin receptor, POMC (pro-opiomelanocortin), MC4R (melanocortin-4 receptor), NTRK2 (tropomyosin receptor kinase B receptor), and SIM1 (single-minded 1 transcription factor).
ObesityMarket Report Key Highlights
-
Key Companies working in the Obesity market include Novo Nordisk, Eli Lilly MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona and many others.
-
Key Therapies involved in Obesity include Tirzepatide, Danuglipron, NYSE: PFE, and many others.
Obesity Treatment Market
Losing weight through healthy eating, increasing physical activity, and making other lifestyle changes are all common therapies for obesity. Some people may benefit from weight-management programs in order to lose weight or avoid regaining it. Some obese persons are either unable to drop enough weight to enhance their health or are unable to maintain their weight loss. Other therapies, such as weight-loss drugs, gadgets, or bariatric surgery, may be considered in such circumstances. Within the first 6 months of treatment, it is recommended to decrease 5–10% of the body weight. It can help reduce the risk of developing obesity-related health problems and improve health conditions associated with obesity, such as high blood pressure and high cholesterol levels. So obesity can be managed by reducing calories and adopting healthier eating habits, physical activity, and weight loss medications like orlistat and phentermine.
Learn more about the Obesity treatment
The Report Covers the Obesity Epidemiology Segmented by:
-
Obesity Incident Cases
-
Obesity Prevalent Cases
-
Obesity treatable cases
-
Obesity diagnosed cases
Obesity Drug Profile and Companies
-
Novo Nordisk : Semaglutide Oral
-
Eli Lilly : Tirzepatide
-
MedImmune : Sibutramine
-
Boehringer Ingelheim : Topiramate
-
Raziel Therapeutics : Danuglipron
-
Altimmune : Semaglutide
-
Saniona : Tirzepatide
And many others.
Learn more about the Obesity Key Companies and Emerging Therapies
Table of Contents
-
Key Insights
-
Obesity Introduction
-
Executive Summary of Obesity
-
Disease Background and Overview
-
Epidemiology and patient population
-
Obesity Emerging Therapies
-
Obesity Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services